Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.